vs
Side-by-side financial comparison of BXP, Inc. (BXP) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $872.1M, roughly 1.2× BXP, Inc.). Hologic runs the higher net margin — 17.1% vs 15.3%, a 1.8% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 0.8%). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs 1.3%).
BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
BXP vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $872.1M | $1.0B |
| Net Profit | $133.0M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | — | 22.6% |
| Net Margin | 15.3% | 17.1% |
| Revenue YoY | 0.8% | 2.5% |
| Net Profit YoY | 53.0% | -10.9% |
| EPS (diluted) | $1.69 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $1.0B | ||
| Q3 25 | $871.5M | $1.0B | ||
| Q2 25 | $868.5M | $1.0B | ||
| Q1 25 | $865.2M | $1.0B | ||
| Q4 24 | $858.6M | $1.0B | ||
| Q3 24 | $859.2M | $988.0M | ||
| Q2 24 | $850.5M | $1.0B |
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $179.1M | ||
| Q3 25 | $-121.7M | $187.2M | ||
| Q2 25 | $89.0M | $194.9M | ||
| Q1 25 | $61.2M | $-17.4M | ||
| Q4 24 | $-228.9M | $201.0M | ||
| Q3 24 | $83.6M | $178.6M | ||
| Q2 24 | $79.6M | $194.5M |
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | 56.0% | ||
| Q3 25 | 59.3% | 55.6% | ||
| Q2 25 | 59.2% | 56.3% | ||
| Q1 25 | 59.2% | 37.5% | ||
| Q4 24 | 59.7% | 56.8% | ||
| Q3 24 | 59.5% | 56.4% | ||
| Q2 24 | 59.8% | 55.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.6% | ||
| Q3 25 | — | 22.6% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 24.1% |
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 17.1% | ||
| Q3 25 | -14.0% | 17.8% | ||
| Q2 25 | 10.2% | 19.0% | ||
| Q1 25 | 7.1% | -1.7% | ||
| Q4 24 | -26.7% | 19.7% | ||
| Q3 24 | 9.7% | 18.1% | ||
| Q2 24 | 9.4% | 19.2% |
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $0.79 | ||
| Q3 25 | $-0.77 | $0.84 | ||
| Q2 25 | $0.56 | $0.86 | ||
| Q1 25 | $0.39 | $-0.08 | ||
| Q4 24 | $-1.46 | $0.87 | ||
| Q3 24 | $0.53 | $0.75 | ||
| Q2 24 | $0.51 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $512.8M | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $7.7B | $5.2B |
| Total Assets | $25.1B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $861.1M | $2.2B | ||
| Q2 25 | $447.0M | $1.9B | ||
| Q1 25 | $398.1M | $1.6B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.4B | $2.3B | ||
| Q2 24 | $685.4M | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $5.2B | ||
| Q3 25 | $5.0B | $5.0B | ||
| Q2 25 | $5.3B | $4.8B | ||
| Q1 25 | $5.3B | $4.6B | ||
| Q4 24 | $5.4B | $4.8B | ||
| Q3 24 | $5.8B | $5.1B | ||
| Q2 24 | $5.8B | $5.0B |
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $9.2B | ||
| Q3 25 | $26.0B | $9.0B | ||
| Q2 25 | $25.6B | $8.8B | ||
| Q1 25 | $25.4B | $8.5B | ||
| Q4 24 | $26.1B | $8.7B | ||
| Q3 24 | $26.4B | $9.2B | ||
| Q2 24 | $25.5B | $8.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | 1.5% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $229.9M | ||
| Q3 25 | $274.2M | $355.1M | ||
| Q2 25 | $353.1M | $343.3M | ||
| Q1 25 | $210.0M | $169.4M | ||
| Q4 24 | $383.7M | $189.3M | ||
| Q3 24 | $286.1M | $367.0M | ||
| Q2 24 | $367.1M | $405.8M |
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $215.2M | ||
| Q3 25 | $231.6M | $341.4M | ||
| Q2 25 | $281.5M | $330.5M | ||
| Q1 25 | $152.6M | $153.9M | ||
| Q4 24 | $312.5M | $172.5M | ||
| Q3 24 | $234.5M | $350.6M | ||
| Q2 24 | $332.4M | $385.3M |
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 20.5% | ||
| Q3 25 | 26.6% | 32.5% | ||
| Q2 25 | 32.4% | 32.3% | ||
| Q1 25 | 17.6% | 15.3% | ||
| Q4 24 | 36.4% | 16.9% | ||
| Q3 24 | 27.3% | 35.5% | ||
| Q2 24 | 39.1% | 38.1% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 1.4% | ||
| Q3 25 | 4.9% | 1.3% | ||
| Q2 25 | 8.2% | 1.3% | ||
| Q1 25 | 6.6% | 1.5% | ||
| Q4 24 | 8.3% | 1.6% | ||
| Q3 24 | 6.0% | 1.7% | ||
| Q2 24 | 4.1% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | 3.97× | 1.76× | ||
| Q1 25 | 3.43× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 3.42× | 2.05× | ||
| Q2 24 | 4.61× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
